Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies.

Dimitrov NV, Leece CM, Tompkins ER, Seymour E, Bennink M, Gardiner J, Crowell J, Hawk E, Nashawaty M, Bennett JL.

Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):201-7.

2.

Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz.

Madhukar BV, Dimitrov NV, Meyer-Leece C, Contreras ML, Crowell J.

Mol Cancer Ther. 2002 Oct;1(12):1125-8.

3.

Clinical pharmacology studies of oltipraz--a potential chemopreventive agent.

Dimitrov NV, Bennett JL, McMillan J, Perloff M, Leece CM, Malone W.

Invest New Drugs. 1992 Nov;10(4):289-98.

PMID:
1487402
4.

Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.

Benson AB 3rd, Olopade OI, Ratain MJ, Rademaker A, Mobarhan S, Stucky-Marshall L, French S, Dolan ME.

Clin Cancer Res. 2000 Oct;6(10):3870-7.

5.

Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose.

O'Dwyer PJ, Szarka C, Brennan JM, Laub PB, Gallo JM.

Clin Cancer Res. 2000 Dec;6(12):4692-6.

6.

Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.

Jacobson LP, Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, Yu LY, Qian GS, Kuang SY, Li YF, Fang X, Zarba A, Chen B, Enger C, Davidson NE, Gorman MB, Gordon GB, Prochaska HJ, Egner PA, Groopman JD, Muñoz A, Helzlsouer KJ, Kensler TW.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):257-65.

7.

Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.

Kim SG, Kim YM, Choi YH, Lee MG, Choi JY, Han JY, Cho SH, Jang JW, Um SH, Chon CY, Lee DH, Jang JJ, Yu ES, Lee YS.

Clin Pharmacol Ther. 2010 Sep;88(3):360-8. doi: 10.1038/clpt.2010.89. Epub 2010 Jul 21.

PMID:
20664537
8.

Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.

Gupta E, Olopade OI, Ratain MJ, Mick R, Baker TM, Berezin FK, Benson AB 3rd, Dolan ME.

Clin Cancer Res. 1995 Oct;1(10):1133-8.

9.

Oltipraz: a laboratory and clinical review.

Benson AB 3rd.

J Cell Biochem Suppl. 1993;17F:278-91. Review.

PMID:
8412206
11.

Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.

Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen B, Wang JS, Zhu YR, Zhang BC, Wang JB, Wu Y, Zhang QN, Qian GS, Kuang SY, Fang X, Li YF, Yu LY, Prochaska HJ, Davidson NE, Gordon GB, Gorman MB, Zarba A, Enger C, Muñoz A, Helzlsouer KJ, et al.

Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):127-34.

12.

Chronic dosing of oltipraz in people at increased risk for colorectal cancer.

Szarka CE, Yao KS, Pfeiffer GR, Balshem AM, Litwin S, Frucht H, Goosenberg EB, Engstrom PF, Clapper ML, O'Dwyer PJ.

Cancer Detect Prev. 2001;25(4):352-61.

PMID:
11531012
13.

Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours.

Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG.

Biopharm Drug Dispos. 2005 Mar;26(2):77-83.

PMID:
15617135
14.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
15.

Safety and efficacy of weekly oral oltipraz in chronic smokers.

Kelley MJ, Glaser EM, Herndon JE 2nd, Becker F, Bhagat R, Zhang YJ, Santella RM, Carmella SG, Hecht SS, Gallot L, Schilder L, Crowell JA, Perloff M, Folz RJ, Bergan RC.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):892-9.

16.

Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China.

Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, Qian GS, Kuang SY, Zarba A, Egner PA, Jacobson LP, Muñoz A, Helzlsouer KJ, Groopman JD, Kensler TW.

J Natl Cancer Inst. 1999 Feb 17;91(4):347-54.

PMID:
10050868
17.

Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.

Pendyala L, Schwartz G, Bolanowska-Higdon W, Hitt S, Zdanowicz J, Murphy M, Lawrence D, Creaven PJ.

Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):269-72.

18.

Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.

Bae SK, Lee SJ, Kim YG, Kim SH, Kim JW, Kim T, Lee MG.

Biopharm Drug Dispos. 2005 Apr;26(3):99-115.

PMID:
15723427
19.

A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.

Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J.

J Eur Acad Dermatol Venereol. 2008 Jan;22(1):19-24. Epub 2007 Nov 19.

PMID:
18031504

Supplemental Content

Support Center